Severe invasive Streptococcus pyogenes infections: A 15-year observational study with molecular characterization of isolates among intensive care adults

Author

Vidaur, Loreto

Azkarate, Izaskun

Salas, Estibaliz

Ansa Isasa, Iñigo

Vicente, Diego

Rello, Jordi

Other authors

Institut Català de la Salut

[Vidaur L] Intensive Care Unit, Donostia University Hospital, Donostia-San Sebastian, Spain. Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Microbiology Department, San Sebastian, Spain. Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. [Azkarate I, Salas E] Intensive Care Unit, Donostia University Hospital, Donostia-San Sebastian, Spain. [Ansa I] Department of Microbiology, Donostia University Hospital-Biogipuzkoa Health Research Institute, San Sebastian, Spain. [Vicente D] Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Microbiology Department, San Sebastian, Spain. Department of Microbiology, Donostia University Hospital-Biogipuzkoa Health Research Institute, San Sebastian, Spain. [Rello J] Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Grup de Recerca Clínica/Innovació en la Pneumònia i Sèpsia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. UR-UM103 IMAGINE, University of Montpellier, Division of Anesthesia Critical Care Pain and Emergency Medicine, Nîmes University Hospital, Montpellier, France

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-11-05T13:26:38Z

2025-11-05T13:26:38Z

2025-10



Abstract

Antimicrobial stewardship; Clindamycin; Mortality


Administració antimicrobiana; Clindamicina; Mortalitat


Administración antimicrobiana; Clindamicina; Mortalidad


Background Improving outcomes among patients with invasive group A Streptococcus pyogenes (iGAS) infections is an unmet clinical need. The main objective of this study was to analyze epidemiological and outcome differences in adults admitted to the intensive care unit (ICU) with iGAS infection over a 15-year period and to evaluate the impact of M1uk isolates and clindamycin optimization on patient outcomes. Methods This was a single-center observational study conducted at the ICU of Donostia University Hospital, located in Donostia, Spain. The recruitment of all consecutive adult patients admitted to the ICU by iGAS was carried out from January 2010 to May 2024 and divided into three periods: pre-pandemic (January 2010–2019), pandemic (2020–2021), and post-pandemic (May 2022–2024). The main outcome variables were ICU length of stay, hospital length of stay, and ICU mortality. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software (version 25; SPSS Inc., Chicago, IL, USA). A significance level of P <0.05 was considered for all analyses. Results Sixty-eight adults were enrolled, with a crude mortality in pre- and post-pandemic periods being 25.5% and 10.0% (P=0.200), respectively. Twenty (29.4%) were respiratory and 29 (41.2%) were soft tissue infections. The incidence had valleys (<1/100,000) in 2020 and 2021 and peaks (>4/100,000 inhabitants) in 2014, 2019, and 2023. Pre-pandemic patients were significantly younger (median: 58.0 vs. 67.5 years, P <0.050), had lower Charlson scores (median: 0 vs. 2, P=0.009), and required more renal replacement therapy (48.9% vs. 15.0%, P=0.013). Emm1 type was the most frequent isolated strain, with the M1uk lineage being represented in 6 out of 7 Emm1 isolates in post-pandemic period. M1uk-infected patients were older (median: 67.0 vs. 50.0 years, P=0.073) but mortality was similar. Most patients (86.6%) received β-lactams plus clindamycin. Interestingly, time to clindamycin administration was earlier (median: 1 h vs. 24 h; P <0.050) in the post-pandemic period with a 5-fold increase in ICU mortality (5.6% to 26.5%, OR=6.14, 95% CI: 0.74 to 50.85; P=0.090) among those adults who did not receive clindamycin in the emergency department. Conclusions The incidence of iGAS infections requiring ICU admission showed no significant increase post-Coronavirus Disease-19 pandemic. The highly toxigenic M1uk strain became predominant, but it was not associated with worse mortality among adult ICU patients.

Document Type

Article
Published version

Language

English

Subjects and keywords

Malalties bacterianes - Epidemiologia; Unitats de cures intensives; Streptococcus pyogenes; Malalties bacterianes - Tractament; Medicaments antiinfecciosos - Ús terapèutic; HEALTH CARE::Health Care Facilities, Manpower, and Services::Health Facilities::Hospital Units::Intensive Care Units; ORGANISMS::Bacteria::Firmicutes::Lactobacillales::Streptococcaceae::Streptococcus::Streptococcus pyogenes; DISEASES::Bacterial Infections and Mycoses::Bacterial Infections; Other subheadings::Other subheadings::Other subheadings::/epidemiology; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents; Other subheadings::Other subheadings::/therapeutic use; ATENCIÓN DE SALUD::instalaciones, servicios y personal de asistencia sanitaria::centros sanitarios::unidades hospitalarias::unidades de cuidados intensivos; ORGANISMOS::Bacteria::Firmicutes::Lactobacillales::Streptococcaceae::Streptococcus::Streptococcus pyogenes; ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas; Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos; Otros calificadores::Otros calificadores::/uso terapéutico

Publisher

Elsevier

Related items

Journal of Intensive Medicine;5(4)

https://doi.org/10.1016/j.jointm.2025.06.001

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)